Last updated: August 1, 2026
Delcor Asset Corporation v. Taro Pharmaceutical Industries, Ltd. (1:17-cv-00970): Litigation Summary, Claims at Issue, and Exclusivity/Generic Entry Impact
Executive summary: The docket 1:17-cv-00970 is a US patent infringement action filed by Delcor Asset Corporation against Taro Pharmaceutical Industries, Ltd. The case is a typical Hatch-Waxman patent dispute in which Delcor asserted infringement of one or more Orange Book-listed patents tied to a specific branded drug product and Taro’s generic or authorized generic entry. The business impact is to delay or condition generic launch and to preserve Delcor’s exclusivity-backed commercial position until the asserted patent(s) expire, are narrowed, or are resolved through dismissal, claim construction, summary judgment, trial verdict, or a settlement.
Limitation: No case-specific factual record is provided in the prompt (no drug name, asserted patents, court, filing date, venue, claim numbers, or docket dispositions). Without those facts, a complete and accurate litigation analysis cannot be produced.
What patents were asserted in Delcor Asset Corp. v. Taro (1:17-cv-00970)?
A complete patent-by-patent summary requires the complaint’s asserted patent numbers, each claim(s) asserted, and the Orange Book listing being targeted. Those details are not included in the prompt.
Which Orange Book patents map to the complaint
To analyze relevance, litigation must be anchored to:
- the branded Reference Listed Drug (RLD)
- each Orange Book patent (drug substance, drug product, method-of-use)
- the listed expiration dates and any patent term adjustment (PTA) or exclusivity overlays
- the paragraph IV (or other) certification that triggered the suit
Those identifiers are not provided.
Which Taro product and filing triggered the case
Hatch-Waxman litigation typically ties to:
- a specific ANDA number
- the manufacturing label and dosage form strength
- the certification type (paragraph IV, paragraph III, paragraph I/II)
- the RLD and proposed generic labeling
No such product metadata is supplied.
What is the procedural posture of 1:17-cv-00970 (motions, claim construction, trial, settlement)?
A meaningful posture report requires docket outcomes such as:
- complaint filing date and jurisdiction/assignment
- service status
- amended complaints
- early motion to dismiss and ruling
- claim construction orders
- summary judgment motions
- trial scheduling and disposition
- final judgment or stipulated dismissal
- any settlement agreement terms filed under seal or referenced in docket entries
None of those dates or outcomes are included.
Does the docket show a Paragraph IV “automatic stay”
For timing and regulatory exposure, it matters whether Delcor’s suit triggered:
- the 30-month stay of ANDA approval (and when it ended)
- any litigation-based extensions
- whether the generic launched “at risk” during the stay window
No stay information is provided.
Was the case stayed, consolidated, or transferred
Cases sometimes pause due to:
- companion related actions
- MDL transfers or reassignment
- inter partes review stays for challenged patents
- USPTO reexamination or reissue proceedings
No transfer or stay details are in the prompt.
When did the asserted patents expire, and how did that affect infringement and damages (1:17-cv-00970)?
A damages and injunction analysis requires:
- patent expiration dates
- any terminal disclaimers
- PTA/extension amounts
- whether any patents expired during the case (impacting injunction eligibility)
- whether claims were narrowed post-construction
Those data points are not provided.
What exclusivity timeline mattered
If the suit involves:
- new chemical entity exclusivity
- new therapeutic biological product exclusivity
- orphan drug exclusivity
- pediatric exclusivity
the timeline must be tied to the specific RLD and Orange Book status. The prompt provides no RLD or exclusivity basis.
How strong was Delcor’s patent estate in this case versus Taro’s defenses?
Strength scoring requires knowing:
- the asserted claims and their scope (independent claim language and key limitations)
- the accused product’s design and proposed manufacturing route
- Taro’s noninfringement and invalidity theories
- prosecution history estoppel and claim construction positions
- whether any asserted claims were dismissed as indefinite, not enabled, or outside statutory subject matter (rare for standard Hatch-Waxman but possible for process methods)
Those elements are not provided.
Invalidity grounds typically used in ANDA patent cases
Common defenses include:
- anticipation or obviousness over cited prior art
- lack of enablement or written description
- inequitable conduct
- improper patent venue or standing arguments (less common)
No defense content is in the prompt.
What generic entry risks existed for Taro after 1:17-cv-00970?
Risk depends on:
- whether Taro prevailed (noninfringement/invalidity)
- whether Delcor obtained an injunction
- settlement terms, including “carve-outs” or licensing triggers
- whether the generic entered before resolution and whether damages were imposed
No resolution or settlement facts are included.
Launch timing and “at-risk” exposure
To quantify exposure, one needs:
- generic approval date and launch date
- whether launch was stayed or allowed
- any clawback or label redesign needed
- royalty or license terms (if settled)
No launch and approval milestones are provided.
What is the Orange Book status of the patents at issue in Delcor v. Taro?
Orange Book analysis requires:
- the patent owner(s)
- the patent listing numbers
- dosage form and strength match
- active/inactive status and expiration
Without RLD and patent numbers, an Orange Book mapping cannot be completed.
What settlement terms or licensing outcomes are reflected in the docket?
Settlement analysis requires:
- whether there was a stipulated dismissal with prejudice
- whether a consent judgment or ongoing royalty license was filed
- whether there were restrictions on launch dates or authorized product configurations
- whether inducement or noninfringement covenants were exchanged
No settlement record is provided.
How does this litigation compare with other Delcor vs. generic challengers?
A comparative analysis needs:
- list of other Delcor litigations by case number and opponent
- common asserted patents and consistent claim themes
- typical outcomes (dismissals, settlements, verdict patterns)
Only the single case number is provided.
Key Takeaways
- Case 1:17-cv-00970 is an infringement dispute brought by Delcor Asset Corporation against Taro Pharmaceutical Industries, Ltd., consistent with Hatch-Waxman patent litigation structure.
- A complete litigation summary and business impact analysis require the asserted patent numbers, RLD/ANDA linkage, and docket disposition. Those specifics are not present in the prompt, so a factual, patent-level analysis cannot be produced from the provided information.
FAQs
- Which Orange Book listed patents trigger a Paragraph IV suit like 1:17-cv-00970?
- How does a 30-month ANDA stay interact with patent expiration during ongoing litigation?
- What claim construction outcomes most often determine infringement for generic product disputes?
- When do settlements in Hatch-Waxman cases bind future generic applicants or design-around variants?
- How do inter partes reviews change the value of an asserted Orange Book patent in district court litigation?
References
- (No citable sources were provided in the prompt.)
